Integrated Global CDMO with the Fundamental Objective to Reduce the Burden of Disease on Patients
Piramal Pharma Solutions (PPS) serves our customers through a globally integrated network of 15 facilities in North America, Europe, and India. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio.
As a company, Piramal Pharma Solutions is poised to react quickly to our customers' needs. The customer experience is something we continuously strive to improve and is ultimately what makes us stand out. In this video, Peter DeYoung, CEO of Piramal Global Pharma, explains what it takes to be a customer centric organization.
In this video, CEO Peter DeYoung explains how PPS supports the market’s evolution through a collection of highly differentiated offerings. With capabilities such as antibody-drug conjugations, oral contraceptives, high potency APIs, vaccines and other biologics, peptide APIs, complex sterile fill/finish, and other specialized services, we are well prepared to offer high value programs to the market.
For CDMOs, the quest to provide in-demand, market-leading services to pharma and biotech clients requires a strong commitment to expansion, innovation, and creative thinking. In this video, CEO Peter DeYoung discusses the strategy and tactics PPS is instilling to be the provider of choice for companies seeking global outsourcing support.
This corporate profile outlines all the services offered by Piramal Pharma Solutions, which can be delivered as both stand-alone capabilities and as integrated programs across multiple sites. Our expertise ranges from discovery to drug substance development & manufacturing, drug product formulations, and commercial supply of APIs and finished dosage forms.
Piramal is recognized globally as a leader in providing customer-centric solutions in the field of antibody-drug conjugations (ADCs) and bioconjugates. Our world-class ADC facility in Grangemouth, Scotland was recently expanded to provide additional capacity in this important and fast-growing market. This brochure provides an overview of our capabilities and important details that validate our leadership position.
Piramal Pharma Solutions offers a broad portfolio of generic APIs, with approximately forty commercialized products currently available and another twelve in development. We also have a library of approximately 30 peptide APIs available or in development. This brochure provides a complete list of products, including DMF and regulatory information.
With more than 60 years experience in API manufacturing, Riverview is recognized as a world-class facility for drug substance manufacturing. The site, which has been fully inspected by numerous regulatory agencies, has extensive experience in safely delivering high potency APIs (HPAPIs) and has advanced several HPAPIs from early development to commercial manufacture.
Based in Hyderabad, India’s Genome Valley, our associate company Yapan Bio has a proven track record of success in developing and manufacturing a variety of large molecules. They provide process development, scale-up, and GMP compliant manufacturing of vaccines and biologics/bio-therapeutics, including high containment product classes (up to BSL-2+), recombinant vaccines, viral vector-based vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics for Phase I/II human clinical trials.
